Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study
| Autor: | Sandro Barni, C. Dellach, Giorgio Mustacchi, Mauro Mansutti, Cosimo Sacco, M. Cozzi, Marina Cazzaniga, Antonio Farris |
|---|---|
| Přispěvatelé: | Mustacchi, G, Mansutti, M, Sacco, C, Barni, S, Farris, A, Cazzaniga, M, Cozzi, M, Dellach, C, Mustacchi, Giorgio, Dellach, C. |
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Endocrine therapy
medicine.medical_specialty medicine.drug_class medicine.medical_treatment Antineoplastic Agents Breast Neoplasms Neo-adjuvant Exemestane chemistry.chemical_compound Breast cancer breast cancer Internal medicine Clinical endpoint Breast-conserving surgery Medicine Humans Adverse effect Aged Aged 80 and over Aromatase inhibitor business.industry neoadjuvant endocrine Cancer Hematology medicine.disease Combined Modality Therapy Surgery Androstadienes Treatment Outcome Oncology chemistry Chemotherapy Adjuvant Female Breast disease business |
| Popis: | Background: The steroidal aromatase inhibitor exemestane has demonstrated efficacy for the treatment of breast cancer in the metastatic and adjuvant settings. Smaller trials have also reported efficacy in the neo-adjuvant setting. Patients and methods: This phase II, open-label, multicentre study examined the efficacy and safety of neo- adjuvant exemestane in women aged >70 years with operable, receptor-rich breast cancer. Consecutive eligible patients received exemestane 25 mg/day for 6 months before planned surgery. The primary end point was clinical response. Results: Overall, 117 patients were recruited (median age 80 years). The objective response rate in 112 assessable patients (85 with clinical and mammographic evaluation; 27 with clinical evaluation only) was 69.6% (two complete responses; 76 partial responses). In patients who responded, median tumour size reduced from 4.81 to 2.12 cm. Seventy-seven patients (68.7%) continued to surgery. Of the 40 patients eligible for breast-conserving surgery, 34 (85%) deemed unfit for this procedure at baseline. Exemestane-related adverse events were unremarkable except for grade 3 allergic skin reactions in two patients (1.8%). Conclusion: Neo-adjuvant exemestane given for 6 months appears to be effective for receptor-rich breast cancer in older patients. There may now be sufficient evidence to support the use of neo-adjuvant in this patient population. Key words: aromatase inhibitor, breast cancer, endocrine therapy, exemestane, neo-adjuvant |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|